3 days ago · Journavx (suzetrigine) is a new non-opioid pain-relieving tablet used to treat short-term moderate to severe pain. includes Journavx side effects, uses, interactions, and more.

6 days ago · The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.

5 days ago · The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment

Jan 30, 2025 · JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain.

5 days ago · The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.

5 days ago · Journavx, Vertex's new non-opioid painkiller, is an alternative for managing moderate-to-severe acute pain without the risk of addiction. Clinical trials showed it provides similar pain relief to opioids, but with fewer side effects.

6 days ago · Journavx has been specifically approved for the treatment of moderate-to-severe acute pain, which often results from injury, surgery, illness, trauma or painful medical procedures, and typically ...

6 days ago · Will the new non-addictive painkiller approved by the FDA take the place of opioid drugs? Who should get a prescription? Northeastern pain and addiction expert Ganesh A. Thakur explains what Journavx means for sufferers of acute and chronic pain.

6 days ago · The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin a

6 days ago · A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.